Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate Elevation
The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Myofibroblasts, the hallmark of fibrotic disease, contribute to the pathology of fibrosis by secreting large amounts of extracellular matrix and contributing to alveolar contraction. Myofibroblasts are characterized by the expression of α-smooth muscle actin (α-SMA), a contractile protein normally associated with smooth muscle cells. Transforming growth factor-β1 (TGF-β1) is a well characterized profibrotic cytokine that induces myofibroblast transformation both in vitro and in vivo. We report here that the lipid mediator prostaglandin E2 (PGE2) inhibits TGF-β1–induced expression of α-SMA in primary fetal and adult lung fibroblasts. This inhibition of α-SMA expression is associated with a reduction in the expression of collagen I. Inhibitory actions of PGE2 are mediated via E prostanoid receptor 2 (EP2) signaling, but not by EP3 signaling, and increases in cyclic adenosine monophosphate production. The inhibitory effects of PGE2 on TGF-β1–induced α-SMA expression are mimicked by an EP2 selective agonist, butaprost, and by forskolin-induced direct activation of adenyl cyclase. An EP2 antagonist blocks the inhibitory effects of PGE2, and an EP3 agonist does not inhibit TGF-β1–mediated increases in α-SMA expression. Our results demonstrate that PGE2 inhibits transition of fibroblasts to myofibroblasts by an EP2 receptor-activated pathway. Augmenting this pathway may serve as a potent antifibrotic therapeutic strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 has similar effects on formation and apoptosis in lung and keloid fibroblasts (145–147).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [147]
Citations
Cites
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243 · cited 1×
“TGF-1 stimulates the expression of -SMA mRNA and protein in myofibroblasts (4, 6, 13 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 2×
“These findings support the prevailing hypothesis that fibrosis is the consequence of dysregulated repair after some form of lung injury ( 2 ).”
BackgroundKhalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505 · cited 1×
“Numerous factors have been identified as promoting the transition of fibroblasts to myofibroblasts, specifically TGF-1, granulocyte macrophage-colony stimulating factor, heparin, and TNF- (12, 29 , 30).”
BackgroundZhang, K., Rekhter, M. D., Gordon, D., & Phan, S. H. (1994) · PubMed · Cited by 480
Wilborn, J., Crofford, L. J., Burdick, M. D., Kunkel, S. L., Strieter, R. M., & Peters-Golden, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117866 · Cited by 392 · cited 3×
“Moreover, fibroblasts cultured from idiopathic pulmonary fibrosis patients exhibit an impaired ability to synthesize PGE2 (21, 22 ), which has been attributed to an inability to appropriately upregulate COX-2 mRNA and protein levels (22, 35).”
BackgroundInfluentialSelf-citationCharacterization of a New Human Diploid Cell Strain, IMR-90
Nichols, W. W., Murphy, D. G., Cristofalo, V. J., Toji, L. H., Greene, A. E., & Dwight, S. A. (1977) · Science · doi:10.1126/science.841339 · Cited by 367 · cited 1×
“Definition of abbreviations: EP, E prostanoid receptor; RT-PCR, reverse transcriptase‐polymerase chain reaction. lung fibroblasts ( 24 ).”
Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L., & Gabbiani, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1595 · Cited by 268 · cited 3×
“Few factors have been identified that inhibit the transformation of myofibroblasts (5, 14 , 15, 31).”
BackgroundResultInfluentialFactors influencing myofibroblast differentiation during wound healing and fibrosis.
Desmoulière, A. (1995) · Cell Biology International · doi:10.1006/cbir.1995.1090 · Cited by 265 · cited 3×
“Among the -SMA inducing factors, TGF- 1i s thought to be the most efficient ( 12 ).”
BackgroundInfluentialKeerthisingam, C. B., Jenkins, R. G., Harrison, N. K., Hernandez-Rodriguez, N. A., Booth, H., Laurent, G. J., Hart, S. L., Foster, M. L., & McAnulty, R. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64092-8 · Cited by 241 · cited 2×
“Animal models have proven that pharmacologic or genetic blockade of prostaglandin production during the evolution of bleomycin-induced pulmonary fibrosis results in worse fibrotic outcomes ( 35 , 36).”
BackgroundZhang, H.-Y., Gharaee‐Kermani, M., Zhang, K., Karmiol, S., & Phan, S. H. (1996) · Europe PMC (PubMed Central) · Cited by 235
Research works printed but not linked: 13
- 2001, Chest, 120(1 Suppl), 77S
- 1981, Am. J. Pathol., 102, 427
- 1989, Lab. Invest., 60, 643
- 1996, Am. J. Pathol., 148, 527
- 1995, Exp. Nephrol., 3, 134
- 1994, Am. J. Pathol., 145, 114
- 1995, Am. J. Pathol., 147, 352
- 1996, Kidney Int. Suppl., 54, S46
- 1985, Am. Rev. Respir. Dis., 131, 94
- 1998, J. Cell. Biochem., 71, 254, 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.0.CO;2-L · doi:10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l
- 1993, Am. J. Pathol., 143, 1754
- 1992, Lab. Invest., 67, 716
- 1995, J. Rheumatol., 22, 1876
Cited by
Fibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression
Liu, F., Mih, J. D., Shea, B. S., Kho, A. T., Sharif, A. S., Tager, A. M., & Tschumperlin, D. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201004082 · Cited by 810
“Because PGE2 acts to suppress TGF-–driven responses in fibroblasts (Kolodsick et al., 2003; Sandulache et al., 2007; Thomas et al., 2007), the COX-2/PGE2 stimulation by TGF- is thought to dampen cellular responses to this fibrogenic cytokine and prevent overexuberant fibrotic reactions.”
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808
Self-citationMultifaceted roles of PGE2 in inflammation and cancer
Nakanishi, M., & Rosenberg, D. W. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0342-8 · Cited by 591
“PGE2 has been shown to inhibit myofibroblast differentiation and limit their collagen secretion during pulmonary fibrosis [60], in lung allografts [61], and in bleomycin-induced skin fibrosis [62].”
Diverse functions of matrix metalloproteinases during fibrosis
Giannandrea, M., & Parks, W. C. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.012062 · Cited by 541
“PGE2 suppresses fibrosis by inhibiting fibroblast migration, proliferation, collagen synthesis and differentiation into myofibroblasts (Huang et al., 2009; Kolodsick et al., 2003; White et al., 2005).”
Background
Metadata
- Authors
- Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., & Moore, B. B.
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, Michigan
- Corresponding author
- Moore, Bethany B.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-01
- Volume
- 29
- Issue
- 5
- Pages
- 537-544
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W1995721099
- Cited by
- 294
- References
- 37
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 7 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 11 · 2016: 10 · 2015: 15 · 2014: 19 · 2013: 16 · 2012: 15
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ca079046-03)
- National Heart, Lung, and Blood Institute (P50HL56402, HL071586, P50HL056402, P50HL60289, 2T32HL07749, R01HL071586, P50HL060289, T32HL007749)
- National Cancer Institute (CA79046)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- prostaglandin E2, myofibroblast differentiation, cyclic AMP, TGF-β1, alpha-smooth muscle actin, type I collagen, pulmonary fibrosis, antifibrotic therapy, butaprost, adenylate cyclase
- MeSH terms
- Cyclic AMP, Cell Differentiation, Fibroblasts, Colforsin, Humans, Dinoprostone, Receptors, Prostaglandin E
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate Elevation. https://app.cochat.ai/papers/10.1165/rcmb.2002-0243oc
- The paper
- Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., & Moore, B. B. (2003). Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate Elevation. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2002-0243oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.